Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.25 USD
+0.04 (0.49%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $8.24 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Company Summary
Cayman Islands-based Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing, and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 — Innoviva, Inc. (then Theravance, Inc.) and Theravance.
Theravance and Viatris have collaborated for the development and commercialization of Yupelri, a long-acting muscarinic antagonist (LAMA), as a once-daily, nebulized treatment of chronic obstructive pulmonary disease (COPD).
Viatris and Theravance are sharing U.S. profits and losses received in connection with the commercialization ...
Company Summary
Cayman Islands-based Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing, and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 — Innoviva, Inc. (then Theravance, Inc.) and Theravance.
Theravance and Viatris have collaborated for the development and commercialization of Yupelri, a long-acting muscarinic antagonist (LAMA), as a once-daily, nebulized treatment of chronic obstructive pulmonary disease (COPD).
Viatris and Theravance are sharing U.S. profits and losses received in connection with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives the remaining 35%. Meanwhile, Theravance is entitled to low double-digit royalties on ex-U.S. net sales. Viatris recognizes product sales from Yupelri. Viatris and also owns a stake in Theravance.
In July 2022, Theravance sold all of its equity interests in Theravance Respiratory Company to Royalty Pharma. The latter will financially support Theravance to clinically develop its pipeline candidate, ampreloxetine, in exchange for certain royalty rights. Ampreloxetine is being developed to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
Following the restructuring plans in September 2021, Theravance is currently focusing on developing its respiratory pipeline.
J&J entered into a collaboration agreement with Theravance in 2018 for izencitinib to treat inflammatory intestinal diseases, including ulcerative colitis (UC) and Crohn’s disease (CD). However, after the failure of the UC study and Theravance’s decision to close the clinical studies on CD, Janssen terminated the contract, effective Jan 16, 2022. Presently izencitinib is being developed by Theravance on its own.
In 2023, Theravance generated revenues of $57.4 million, which increased 11.8% year over year.
General Information
Theravance Biopharma, Inc
901 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-808-6000
Fax: NA
Web: http://www.theravance.com
Email: investor.relations@theravance.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.10 |
Current Year EPS Consensus Estimate | -0.45 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 8.21 |
52 Week High | 11.71 |
52 Week Low | 7.44 |
Beta | 0.25 |
20 Day Moving Average | 530,859.62 |
Target Price Consensus | 13.75 |
4 Week | -14.42 |
12 Week | -5.93 |
YTD | -26.60 |
4 Week | -18.99 |
12 Week | -10.95 |
YTD | -38.02 |
Shares Outstanding (millions) | 48.92 |
Market Capitalization (millions) | 403.61 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -21.43% |
vs. Previous Quarter | -41.67% |
vs. Previous Year | 3.69% |
vs. Previous Quarter | -1.70% |
Price/Book | 2.07 |
Price/Cash Flow | NA |
Price / Sales | 6.51 |
6/30/24 | -21.29 |
3/31/24 | -18.97 |
12/31/23 | -19.31 |
6/30/24 | -11.94 |
3/31/24 | -11.10 |
12/31/23 | -12.03 |
6/30/24 | 5.20 |
3/31/24 | 5.74 |
12/31/23 | 5.39 |
6/30/24 | 5.20 |
3/31/24 | 5.74 |
12/31/23 | 5.39 |
6/30/24 | -73.61 |
3/31/24 | -72.79 |
12/31/23 | -93.28 |
6/30/24 | -73.61 |
3/31/24 | -72.79 |
12/31/23 | -96.12 |
6/30/24 | -61.63 |
3/31/24 | -60.46 |
12/31/23 | -85.80 |
6/30/24 | 3.98 |
3/31/24 | 4.22 |
12/31/23 | 4.28 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |